At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Gamma Tocopherol +1 moredrug
Likely dose
Gamma Tocopherol 700 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized, Double Blinded, Placebo-controlled Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults
In Brief
A Phase 2 clinical trial evaluating Gamma Tocopherol and Placebo for Airway Inflammation and Asthma. Completed, enrolled 16 participants across 1 site.
Detailed Summary
Purpose: To determine the efficacy of 1400 mg gamma tocopherol-enriched supplement for mitigating inhaled wood smoke particle-induced airway inflammation in healthy adults with no more than mild asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAirway Inflammation, Asthma
CountriesUnited States
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartJun 2018
Primary CompletionMar 2023
Study CompletionMar 2023
TodayJul 2026
First PostedFeb 23, 2018
Enrollment StartJun 8, 2018
Primary CompletionMar 2, 2023
Study CompletionMar 6, 2023
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 8.4 years ago
Interventions
Gamma Tocopheroldrug
Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.
Placebodrug
Each dose consists of two capsules by mouth once daily for a total of 7 days.